uniQure (NASDAQ:QURE) Upgraded at Wells Fargo & Company

Wells Fargo & Company upgraded shares of uniQure (NASDAQ:QURE) from a hold rating to a strong-buy rating in a research report released on Tuesday morning,Zacks.com reports.

Several other equities analysts have also issued reports on the company. StockNews.com upgraded uniQure to a “sell” rating in a research report on Wednesday. Raymond James upgraded uniQure from an “outperform” rating to a “strong-buy” rating and raised their price target for the stock from $20.00 to $52.00 in a research report on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of uniQure in a report on Tuesday. Guggenheim reiterated a “buy” rating on shares of uniQure in a report on Wednesday. Finally, The Goldman Sachs Group dropped their price objective on uniQure from $10.00 to $9.00 and set a “neutral” rating for the company in a report on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, two have given a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, uniQure currently has a consensus rating of “Moderate Buy” and an average price target of $32.14.

uniQure Price Performance

Shares of uniQure stock opened at $15.06 on Tuesday. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The firm has a market capitalization of $734.07 million, a PE ratio of -3.04 and a beta of 0.89. The business’s 50-day moving average price is $6.85 and its 200-day moving average price is $6.28. uniQure has a 12 month low of $3.73 and a 12 month high of $17.39.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The firm had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.73 million. Sell-side analysts forecast that uniQure will post -3.74 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction on Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the transaction, the chief executive officer now directly owns 597,915 shares in the company, valued at approximately $4,562,091.45. The trade was a 0.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 4.74% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On uniQure

Institutional investors and hedge funds have recently bought and sold shares of the stock. RTW Investments LP purchased a new position in shares of uniQure in the third quarter valued at about $49,000. China Universal Asset Management Co. Ltd. lifted its position in shares of uniQure by 57.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 3,663 shares in the last quarter. Atria Investments Inc purchased a new position in shares of uniQure in the third quarter valued at about $53,000. Quarry LP purchased a new position in shares of uniQure in the third quarter valued at about $58,000. Finally, Vanguard Personalized Indexing Management LLC lifted its position in shares of uniQure by 21.0% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 2,306 shares in the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.